Objective: To observe the effects of Montelukast combined Budesonide formotello on exhaled nitric oxide (FeNO) and pulmonary function of cough variant asthma (CVA) patients. Methods: 60 CVA patients were randomly divided into observation group and control group with 30 patients in each group. The patients in control group were treated with Budesonide formoterol inhalation; While the patients in observation group were treated with Budesonide formoterol inhalation combined Montelukast. The FeNO and pulmonary function of patients in both groups were compared after treating for 4 weeks. Results: After treatment, the FeNO of patients in 2 groups were all significantly decreased (P<0.05); And the FeNO of patients in observation group after treatment was significantly lower than control group (P<0.05). After treatment, the forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC of both groups increased significantly (P<0.05); And, the FEV1, FVC and FEV1/FVC of patients in observation group after treatment was significantly lower than control group (P<0.05). Conclusions: Compared with Budesonide formotello alone, treating CVA with Montelukast Combined Budesonide formotello can inhibit respiratory inflammation and improve pulmonary function better, so it is worthy of clinical application.